Cisapride (R 51619): A Precision Tool for Cardiac Electrophysiology and Predictive Cardiotoxicity Research

Principle Overview: Dual Modulation of 5-HT4 and hERG Pathways

Cisapride (R 51619) is a chemically robust, nonselective 5-HT4 receptor agonist and a potent inhibitor of the hERG potassium channel. This dual functionality makes it a cornerstone in cardiac electrophysiology research, where precise modulation of 5-HT4 receptor signaling and hERG channel inhibition models arrhythmogenic risk and gastrointestinal motility under controlled conditions. Its high purity (>99.7%) and comprehensive QC profile ensure reproducibility, while solubility in DMSO (≥23.3 mg/mL) and ethanol (≥3.47 mg/mL) support diverse experimental designs.

At the intersection of pharmacology and translational biology, Cisapride (also known as cisaprode, cisparide, or cispride) enables researchers to probe the molecular underpinnings of cardiac arrhythmias, dissect 5-HT4-mediated signal transduction, and evaluate drug-induced cardiotoxicity in both primary cells and stem-cell-derived systems.

Step-by-Step Workflow: Enhancing Cardiac and GI Research Protocols

1. Compound Preparation and Handling

• Stock Solution: Dissolve Cisapride in DMSO to prepare a 10–30 mM stock solution. Ensure complete dissolution by gentle vortexing and avoid prolonged sonication to prevent degradation.
• Aliquoting and Storage: Dispense small aliquots (10–100 μL) to minimize freeze–thaw cycles. Store solids at -20°C; avoid long-term storage of solutions—freshly prepared aliquots improve consistency.

2. Experimental Design in Cardiac Electrophysiology

• Model Selection: For high-content phenotypic screening, induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) are preferred. These cells recapitulate human cardiac electrophysiology and are amenable to high-throughput analysis (Grafton et al., 2021).
• Dosing Strategy: Typical working concentrations range from 10 nM to 10 μM, depending on assay sensitivity. For hERG assays, 100 nM–1 μM captures the maximal inhibition window.
• Controls: Include vehicle controls (DMSO alone) and reference hERG inhibitors (e.g., dofetilide) for benchmarking.

3. Cardiac Arrhythmia and hERG Channel Inhibition Assays

• Patch-Clamp Electrophysiology: Employ automated or manual patch-clamp systems to quantify hERG current inhibition. Cisapride demonstrates potent IC₅₀ values in the low nanomolar range, enabling detection of subtle arrhythmogenic effects.
• High-Content Imaging: Use deep learning-driven image analysis to capture phenotypic changes in iPSC-CMs, as validated in recent high-throughput screens (Grafton et al., 2021).
• Gastrointestinal Motility Models: Leverage Cisapride’s 5-HT4 agonism to stimulate enteric neuronal activity in ex vivo tissue baths or organoid models, quantifying contractility or peristalsis rates.

4. Data Analysis and Phenotypic Readouts

• Cardiotoxicity Scoring: Adopt single-parameter or multiparametric scoring systems, integrating beat rate, amplitude, and arrhythmic events. Deep learning models can rapidly flag compounds with high cardiotoxic liability—as demonstrated by Grafton et al., where 1280 bioactive molecules were screened and Cisapride emerged as a top hERG inhibitor.
• Comparative Profiling: Contrast Cisapride-treated samples with reference compounds to delineate unique 5-HT4 signaling effects versus pure hERG inhibition.

Advanced Applications and Comparative Advantages

Cisapride (R 51619) distinguishes itself by enabling:

• Mechanistic Dissection: Its nonselective 5-HT4 agonism plus potent hERG inhibition allows researchers to disentangle overlapping pro-arrhythmic and pro-motility effects in the same model system.
• Safety Pharmacology Screens: As highlighted in "Cisapride (R 51619): Advancing Cardiac Electrophysiology ...", this compound streamlines workflows for assessing cardiac risk, complementing deep phenotyping approaches.
• Deep Learning Integration: The referenced Grafton et al. study demonstrates how high-content imaging combined with machine learning can sensitively detect subtle arrhythmogenic signals attributable to hERG channel inhibition by Cisapride, accelerating lead optimization and de-risking pipelines.
• Translational Relevance: As reviewed in "Cisapride (R 51619): A Precision Probe in Cardiac and GI ...", the compound’s dual mechanism provides a bridge between in vitro pharmacology and clinical phenomena, especially when used in iPSC-CM and GI organoid models.

Compared to other hERG inhibitors or selective 5-HT4 agonists, Cisapride’s dual action saves time and resources by reducing the need for multiple probe compounds, thus supporting streamlined, multiparametric screens.

Extending the Literature: Synergy and Distinctions

The advanced use of Cisapride in predictive cardiotoxicity is further explored in "Cisapride (R 51619): Decoding Cardiotoxicity with Deep Learning...", which extends the eLife study by detailing integration with phenomic profiling. Meanwhile, "Cisapride (R 51619): Precision Tool for Cardiotoxicity and GI Research" complements this workflow by highlighting state-of-the-art GI motility models, demonstrating how Cisapride enables cross-system investigations.

Troubleshooting and Optimization Tips

• Solubility Management: For assays requiring aqueous conditions, ensure Cisapride stock is prepared in DMSO and diluted immediately prior to use. Final DMSO concentration should be ≤0.1% to avoid solvent effects on cell physiology.
• Batch Consistency: Always reference the batch-specific HPLC and NMR documentation supplied, as even high-purity lots may exhibit minor batch-to-batch variations affecting ultra-sensitive assays.
• Assay Sensitivity: In iPSC-CMs, optimize cell density and maturation time to maximize signal-to-noise in phenotypic screens. Immature cardiomyocytes may under-respond or display atypical beating patterns, confounding results.
• Compound Stability: Avoid repeated freeze–thaw cycles of Cisapride solutions; thaw aliquots only when needed and discard unused portions. For long experiments, prepare fresh working dilutions daily.
• Deep Learning Artifacts: When using automated phenotypic scoring (per Grafton et al.), ensure imaging parameters (exposure, focus) are standardized to avoid false positives/negatives from non-biological variation.

Future Outlook: Towards Next-Generation Safety and Translational Models

As the field pivots toward more predictive, human-relevant safety assays, Cisapride (R 51619) remains central to both methodological innovation and translational insight. With the convergence of iPSC technology, deep phenotyping, and machine learning, researchers now have the tools to identify and mitigate cardiotoxic risk earlier in the drug development pipeline.

Emerging applications include multiplexed screening for off-target arrhythmogenicity, integration with CRISPR-edited iPSC lines carrying patient-specific mutations, and cross-system modeling of cardiac–gastrointestinal interactions. As highlighted in the complementing literature, Cisapride’s unique dual action positions it as an essential tool for next-generation phenotypic discovery, safety pharmacology, and mechanistic dissection.

Visit the Cisapride (R 51619) product page for detailed specifications, QC data, and ordering information to accelerate your cardiac and GI research workflows.